Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Concurrent Chemo/Radiation in Small Cell Lung Cancer
NCT02402920Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in small cell lung cancer (SCLC) and Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicity. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02402920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402920.